scholarly journals Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report

2021 ◽  
Vol 62 (3) ◽  
Keyword(s):  
Treatment Options ◽  
Supportive Therapy ◽  
Compassionate Use ◽  
Mechanically Ventilated ◽  
Allogenic Bone ◽  
The Family ◽  
Good General Condition ◽  
Stem Cell Treatment ◽  
Attending Physicians ◽  
Mesenchymal Stem Cell Treatment

COVID-19 presentations range from cold-like symptoms to severe symptoms with the development of acute respiratory distress syndrome (ARDS). We report on a severe COVID-19 patient who was mechanically ventilated and who developed ARDS and bacterial infection. Because of rapid clinical deterioration and the exhaustion of other treatment options, the family and attending physicians requested a compassionate use of adult allogenic bone marrow-derived mesenchymal stem cells (MSC) in addition to commonly used immunosuppressive, antiviral, and supportive therapy. The clinical course is discussed thoroughly, with a special emphasis on the safety and effect of MSC therapy. Compassionate MSC treatment, given in three rounds, affected ARDS regression. The patient was discharged from the intensive care unit after 31 days and from hospital after 49 days in a good general condition. MSC treatment was not associated with any side effects and was well tolerated in a three-week period; therefore, it should be studied in larger trials and considered for compassionate use.

Gene Therapy for Inherited Retinopathies: Update on Development Progress

2018 ◽  
Vol 2 (4) ◽  
pp. 219-226
Author(s):  
Susan Sun ◽  
Sandra R. Montezuma
Keyword(s):  
Gene Therapy ◽  
Genetic Disorders ◽  
Treatment Options ◽  
Genetic Material ◽  
Disease Process ◽  
Supportive Therapy ◽  
The Us ◽  
Retinal Disorders ◽  
The Status ◽  
Therapy Treatment

Inherited retinopathies are a group of genetic disorders that lead to blindness and/or vision impairment. Until now, treatment options for inherited retinopathies largely remained limited to supportive therapy. Gene therapy is an attractive therapeutic technique that allows repair of diseased genes, and it has shown success in vision improvement for patients affected by retinal disorders caused by genetic mutations. The US Food and Drug Administration approved the first gene therapy treatment for the eye, indicated for biallelic RPE65 mutation associated Leber congenital amaurosis (LCA), in December of 2017. Additionally, results from other ongoing clinical trials could further establish gene therapy as the milestone treatment that plays a role in disease process reversal for inherited retinopathies. This review article provides an update on the status of gene therapy for treatment of a variety of retinopathies, including LCA, choroideremia, achromatopsia, Stargardt disease, X-linked retinitis pigmentosa, and X-linked retinoschisis. Furthermore, this article explores transport methods of the genetic material, as well as therapy-delivery approaches used in the clinical setting.

scholarly journals FP456CD362+ MESENCHYMAL STEM CELL TREATMENT OF KIDNEY DISEASE IN TYPE 2 DIABETIC LEPR DB/DB MICE

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii223-iii224 ◽  
Author(s):  
Satish Kumar Devarapu ◽  
Xie Junhui ◽  
Murthy Darisipudi ◽  
Anais Rocanin Arjo ◽  
Hans Joachim Anders
Keyword(s):  
Stem Cell ◽  
Kidney Disease ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Treatment ◽  
Mesenchymal Stem Cell Treatment ◽  
Type 2 Diabetic

scholarly journals The emergence of novel coronavirus disease, global treatment update and its containment strategies in overpopulated countries: A Review

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Fazli Azim ◽  
Md Shahidul Islam ◽  
Hedaeytullah Saju ◽  
Kaniz Fatema ◽  
Aneela Hayat ◽  
...  
Keyword(s):  
Cell Attachment ◽  
Antiviral Treatment ◽  
Treatment Options ◽  
Supportive Therapy ◽  
The Public ◽  
Drug Candidates ◽  
Cell Based Therapy ◽  
Research Activities ◽  
Host Cell Attachment ◽  
Novel Coronavirus

: The ongoing pandemic of the novel coronavirus SARS-CoV-2 (COVID-19), has created a major challenge for the public health worldwide. The reported cases indicate the outbreak is more widespread than initially assumed. Around 18 million people have been infected with 689,000 reported deaths (August 2020; number is increasing daily) by this novel coronavirus, with a high mutation rate this poses even more serious threat worldwide. The actual source of COVID-19 is still unclear, even if the initial reports links it to the Chinese seafood wet markets in Wuhan, other animals such as birds, snakes, and many small mammals including bats are also linked with this novel coronavirus. Structure of the COVID-19 shows distinctive proteins among which, spike proteins have a pivotal role in host cell attachment and virus-cell membrane fusion in order to facilitate virus infection. Currently, no specific antiviral treatment or vaccine is available. Various drug candidates including SARS‐CoV and MERS‐CoV protease inhibitors, neuraminidase inhibitors, RNA synthesis inhibitors, ACE2 inhibitors and lungs supportive therapy are on the trail. Cell-based therapy also appeared with remarkable treatment possibilities. In this article, we endeavored to succinctly cover the current and available treatment options including pharmaceuticals, cell-based therapy, and traditional medicine. We also focused on the extent of damages by this novel coronavirus in India, Pakistan, and Bangladesh, the strategies adopted and the research activities initiated so far by these densely populated countries (neighboring China) are explained in this review.

scholarly journals Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease

Medicine ◽  
2018 ◽  
Vol 97 (16) ◽  
pp. e0515 ◽  
Author(s):  
Yanhong Li ◽  
Zhongming Wang ◽  
Yi Zhao ◽  
Yubin Luo ◽  
Wangdong Xu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Behçet Disease ◽  
Leg Ulcers ◽  
Behcet Disease ◽  
Stem Cell Treatment ◽  
Mesenchymal Stem Cell Treatment

Shark teeth: a case of multiple supernumerary teeth

2021 ◽  
Vol 14 (3) ◽  
pp. 135-137
Author(s):  
Fionnuala Loy ◽  
Victoria Elton
Keyword(s):  
Computed Tomography ◽  
Cone Beam Computed Tomography ◽  
Unusual Case ◽  
Treatment Options ◽  
Cone Beam ◽  
Supernumerary Teeth ◽  
Shark Teeth ◽  
Adjacent Structures ◽  
The Family ◽  
Dental Hospital

A 44-year-old male was referred to the Department of Orthodontics at Manchester Dental Hospital. He presented with pain from his heavily restored, lower right second premolar, which had an apical supplemental tooth, visible radiographically. The dentist queried whether the second premolar tooth could be extracted and the supplemental tooth aligned in its place. Clinical examination revealed no relevant abnormalities. The family and medical history were non-contributory. Panoramic tomography revealed multiple supplemental supernumerary teeth in the canine and premolar regions. Cone beam computed tomography and multidisciplinary team input were required to plan the treatment for this unusual case. CPD/Clinical Relevance: These findings highlight the management and treatment options for a case of non-syndromic, multiple supernumerary teeth. Consideration must be given to the risk of damage to adjacent structures if surgically removing supernumerary teeth, and the risk that supernumerary teeth may be ankylosed and not amenable to alignment within the arch.

The Saikewicz Decision: A Medical Viewpoint

1978 ◽  
Vol 4 (3) ◽  
pp. 233-242
Author(s):  
Arnold S. Relman
Keyword(s):  
England Journal ◽  
Acute Leukemia ◽  
New England ◽  
Treatment Decision ◽  
Next Of Kin ◽  
Incompetent Patient ◽  
Medical Tradition ◽  
The Family ◽  
Attending Physicians ◽  
Seriously Ill

AbstractIn this Article, Dr. Arnold S. Relman, the Editor of The New England Journal of Medicine, takes issue with the 1977 Saikewicz decision of the Massachusetts Supreme Judicial Court, which addressed the question of whether chemotherapy should be provided to a severely retarded 67-year-old man who had developed acute leukemia. Dr. Relman interprets Saikewicz as requiring that medical treatment decisions involving the life or death of incompetent patients must receive judicial resolution instead of resolution by the patient's family and physicians. This rule, he asserts, violates medical tradition, and its application will result in serious problems, such as the unnecessary prolongation of the suffering of many seriously ill persons. Dr. Relman proposes, as an alternative to the Saikewicz approach, that in such cases judicial resolution should occur only when there is disagreement, concerning treatment, among next of kin, or between next of kin and attending physicians, or when there is a complaint of injury or of wrongdoing. In all other situations, resolution solely by next of kin and attending physicians should be sufficient. Adequate protection of the interests of the incompetent patient could be achieved by a requirement that the physician in charge document in the medical record that the treatment decision received the concurrence of the family and advance approval of a group of the physician's professional colleagues who have no vested interest in the outcome of the decision.

Topically applied adipose-derived mesenchymal stem cell treatment in experimental focal cerebral ischemia

2020 ◽  
Vol 71 ◽  
pp. 226-233
Author(s):  
Ping Kuen Lam ◽  
Kevin Ka Wang Wang ◽  
Don Wai Ching Chin ◽  
Cindy See Wai Tong ◽  
Yixiang Wang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cerebral Ischemia ◽  
Mesenchymal Stem Cell ◽  
Focal Cerebral Ischemia ◽  
Stem Cell Treatment ◽  
Mesenchymal Stem Cell Treatment
Sign in / Sign up

Export Citation Format

Share Document